Literature DB >> 29237899

Role of surgical treatment for hepatolithiasis-associated intrahepatic cholangiocarcinoma: A retrospective study in a single institution.

Jian Xiao1, Jisheng Zhu1, Zhanying Liu1, Renhua Wan1, Yong Li1, Weidong Xiao1.   

Abstract

CONTEXT: The extent of hepatectomy and lymph node dissection (LND) in the treatment of hepatolithiasis-associated intrahepatic cholangiocarcinoma (HL-iCCA) is still controversial. AIMS: The aim of this retrospective study was to evaluate the role of surgical treatment for HL-iCCA.
METHODS: The clinical data of 63 patients with HL-iCCA who undergoing surgery between January 2005 and December 2015 were analyzed retrospectively. STATISTICAL ANALYSIS USED: All data were analyzed by the SPSS 17.0 software program (IMB Inc., Chicago, IL, USA). Survival curves were analyzed by the Kaplan-Meier method and compared by the Log-rank test. A P < 0.05 was considered statistically significant.
RESULTS: Forty-nine patients (77.8%) underwent surgical resection including 35 with LND and 14 without LND. The overall 1-, 3-, and 5-year survival rates were 58.1%, 28.2%, and 10.6%, respectively, and the median survival time was 19 months. The 1-, 3-, and 5-year survival rates of resection group were 78.9%, 36.3%, and 13.5%, respectively, while the 1-year survival rate of exploratory laparotomy group was 0 (P < 0.0001). The 1-, 3-, and 5-year survival rates of patients with LND were significantly superior to those of without LND (75.9%, 39.4%, and 20.2% vs. 71.4%, 17.9%, and 0, P = 0.043). According to the N status, the 1-, 3-, and 5-year survival rates of pN0 subgroup were 81.8%, 49.2%, and 28.1%; pN1 subgroup were 65.3%, 18.6%, and 0%; and pNx subgroup were 71.4%, 17.9%, and 0%, respectively (pN0 vs. pN1, P = 0.005; pN0 vs. pNx, P = 0.004; pN1 vs. pNx, P = 0.653). The 1-, 3-, and 5-year survival rates of R0 resection (n = 42) were 80.2%, 36.7%, and 14.9%, respectively, and those of R1 resection (n = 7) were 71.4%, 0%, and 0%, respectively (P = 0.028).
CONCLUSIONS: Radical resection is the most effective therapy for HL-iCCA. Regional lymphadenectomy is strongly recommended in resectable HL-iCCA, which is helpful in tumor staging and long-term survival.

Entities:  

Mesh:

Year:  2017        PMID: 29237899     DOI: 10.4103/jcrt.JCRT_356_17

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Hepatolithiasis: clinical series, review and current management strategy.

Authors:  Osman Nuri Dilek; Ahmet Atasever; Nihan Acar; Şebnem Karasu; Emine Özlem Gür; Oğuzhan Özşay; Hakan Çamyar; Fatma Hüsniye Dilek
Journal:  Turk J Surg       Date:  2020-12-29

2.  Down-regulation of lncRNA-NEF indicates poor prognosis in intrahepatic cholangiocarcinoma.

Authors:  Zhanqiang Liang; Bingshuai Zhu; Dongdong Meng; Xiwen Shen; Xuemin Li; Zhongzhen Wang; Liantao Li
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

3.  Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.

Authors:  Tingting Shi; Jian Gong; Koji Fujita; Noriko Nishiyama; Hisakazu Iwama; Shi Liu; Mai Nakahara; Hirohito Yoneyama; Asahiro Morishita; Takako Nonura; Hideki Kobara; Keiichi Okano; Yasuyuki Suzuki; Tsutomu Masaki
Journal:  Int J Oncol       Date:  2020-12-30       Impact factor: 5.650

Review 4.  Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Feiyu Li; Yong Jiang; Liyong Jiang; Qingbin Li; Xiangyu Yan; Songhan Huang; Ji Chen; Shuai Yuan; Yingda Fu; Jun Liu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

5.  Identification of Cholangiocarcinoma Associated with Hepatolithiasis via the Combination of miRNA and Ultrasound.

Authors:  Wei Jiang; Xiaofei Deng; Ting Zhu; Yuya Wei; Zhen Lei; Meimei Guo; Jiong Yang
Journal:  Cancer Manag Res       Date:  2020-03-12       Impact factor: 3.989

6.  Long-term efficacy and advantages of minimally invasive hepatectomy for hepatolithiasis: A protocol for systematic review and meta-analysis.

Authors:  Jianyang Liu; Jinchai Xu; Dengpan Luo; Yujun Zhao; Hongbo Shen; Jianzhong Rao
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.